ConductScience.org, home

Trial · NCT03366103

Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryNumber of Participants With Dose Limiting Toxicities (Phase I)Up to 30 days after last treatment, an average of 3 months
Graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0. The number of participants with dose limiting toxicities at each dose level will be reported with exact binomial 95% confidence intervals. All patients who receive at least 1 dose of both study drugs, regardless of their eligibility for the study, will be evaluable for toxicity.
PrimaryOverall Response Rate (ORR) (Phase II)Up to 1.5 years
Defined as Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. partial response or complete response, of the combination in patients with recurrent small cell lung cancer. The ORR will be reported with its corresponding 95% confidence interval.
SecondaryOccurrence of a Bi-directional Pharmacokinetic (PK) InteractionThrough Day 15Concentrations of each study agent present in the blood at the specified time point are reported for each study agent.
SecondaryNumber of Participants Experiencing Adverse Events by Grade (Phase II)Up to 1.5 yearsGraded by NCI CTCAE v 4.0. The number of participants with toxicities by grade in the phase 2 study will be reported with exact binomial 95% confidence intervals.
SecondaryProgression Free Survival (PFS) (Phase II)Up to 1.5 yearsBased on RECIST 1.1. Standard life table methods will be used to analyze PFS. We will report the one-year and median PFS with 95% confidence intervals.
SecondaryOverall Survival (OS) at Year 1 (Phase II)At Year 1Standard life table methods will be used to analyze OS. We will report the one-year and median OS with 95% confidence intervals.
SecondaryDisease Control Rate (Phase II)Up to 1.5 yearsBased on RECIST 1.1. The proportion of patients achieving disease control will be reported with exact 95% binomial confidence intervals.
OtherChange in p4EBP1 ExpressionBaseline up to 1.5 yearsDescriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
OtherChange in Ratio p4EBP1/4EBP1Baseline up to 1.5 yearsDescriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
OtherChange in Ratio pS6/S6Baseline up to 1.5 yearsDescriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
OtherChange in BAX and MCl-1 ExpressionBaseline up to 1.5 yearsDescriptive statistics and box plots with jittered data points will be used to visualize all raw data. Will be assessed with paired t-tests.
OtherPharmacodynamic ParametersUp to 1.5 yearsExploratory correlative studies with pharmacodynamic (biological endpoints, toxicity and efficacy) will be analyzed using nonparametric statistics.

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03366103/registered